Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery

Eilon Ram, Leonid Sternik, Robert Klempfner, Michael Eldar, Ilan Goldenberg, Yael Peled, Ehud Raanani, Alexander Kogan

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The phosphodiesterase-5 inhibitor sildenafil was developed for the treatment of pulmonary hypertension. The authors investigated the efficacy and safety of sildenafil in the early postoperative period after mitral valve surgery in patients with pulmonary hypertension. Design: A double-blind, placebo-controlled randomized trial was performed. Setting: The trial was performed in a single tertiary referral center. Participants: Fifty consecutive patients who experienced pulmonary hypertension and underwent mitral valve surgery. Interventions: Patients were randomly assigned to the following 2 groups: 25 patients received 20 mg sildenafil every 8 hours, and the remaining 25 patients received placebo during the same period. Hemodynamic parameters were studied by using a pulmonary artery catheter at baseline and every 6 hours up to 36 hours. Results: Patients who received sildenafil showed a decrease in mean pulmonary pressure, from 32 ± 7 mmHg at baseline to 26 ± 3 mmHg after 36 hours, whereas no change was seen in patients who received placebo (mean pulmonary pressure 34 ± 6 mmHg at baseline and 35 ± 5 mmHg after 36 h) (p < 0.001). No significant changes in systemic hemodynamic and oxygenation were observed. Patients who received sildenafil compared with those who received placebo had a median mechanical lung ventilation time of 16 (10-31) hours versus 19 (13-41) hours (p = 0.431), intensive care unit stay of 74 (44-106) hours versus 91 (66-141) hours (p = 0.410), and a total hospitalization stay of 7 (5-10) days versus 11 (7-15) days (p = 0.009). Conclusions: The immediate postoperative administration of sildenafil after mitral valve surgery is safe. Sildenafil demonstrates a favorable decreasing effect on pulmonary vascular pressure without systemic hypotension and ventilation–perfusion mismatch.

Original languageEnglish
Pages (from-to)1648-1656
Number of pages9
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume33
Issue number6
DOIs
StatePublished - Jun 2019

Keywords

  • mitral valve
  • phosphodiesterase-5 inhibitor
  • secondary pulmonary hypertension
  • sildenafil

Fingerprint

Dive into the research topics of 'Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery'. Together they form a unique fingerprint.

Cite this